US Bancorp’s Zentalis Pharmaceuticals ZNTL Stock Holding History

US Bancorp’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,164	Closed	-$1.35K	–	4315
2025 Q2	$1.35K	Sell	1,164 -8,135	-87%	-$10.7K	﹤0.01%	3920
2025 Q1	$14.8K	Buy	+9,299	New	+$20.1K	﹤0.01%	3303
2024 Q4	–	Sell	-383	Closed	-$1.41K	–	4277
2024 Q3	$1.41K	Sell	383 -626	-62%	-$2.27K	﹤0.01%	3849
2024 Q2	$4.13K	Buy	1,009 +359	+55%	+$4.01K	﹤0.01%	3573
2024 Q1	$10.2K	Sell	650 -8	-1%	-$110	﹤0.01%	3329
2023 Q4	$9.97K	Sell	658 -229	-26%	-$3.34K	﹤0.01%	3316
2023 Q3	$17.8K	Hold	887	–	–	﹤0.01%	2938
2023 Q2	$25K	Buy	887 +417	+89%	+$10K	﹤0.01%	2868
2023 Q1	$8.08K	Buy	470 +442	+1,579%	+$8.95K	﹤0.01%	3358
2022 Q4	$564	Hold	28	–	–	﹤0.01%	3988
2022 Q3	$1K	Sell	28 -1,248	-98%	-$34.1K	﹤0.01%	4024
2022 Q2	$36K	Sell	1,276 -175	-12%	-$4.63K	﹤0.01%	2773
2022 Q1	$67K	Buy	1,451 +1,148	+379%	+$61.9K	﹤0.01%	2470
2021 Q4	$25K	Buy	+303	New	+$23.4K	﹤0.01%	2999

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

US Bancorp's ZNTL Position: Q3 2025 in Review

US Bancorp sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 1,164 shares — an estimated $1.35K sold.

US Bancorp first reported a position in ZNTL in Q4 2021 and held it in 14 quarters. The position peaked at $67K in Q1 2022. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

US Bancorp reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
US Bancorp sold 1,164 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $1.35K.
US Bancorp first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 14 quarters.
US Bancorp's Zentalis Pharmaceuticals position peaked at $67K in Q1 2022.
99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on US Bancorp's 13F filing for Q3 2025, filed 12 Nov 2025.